Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333818 | 0.88 | ADORA3 (0.45) | BRAFKDM4EALDH1A1HPGDADORA3 | |
| SCHEMBL4359201 | 0.85 | MAP4K4 (0.53) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL3334682 | 0.85 | HTT (0.50) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL4351159 | 0.83 | BRAF (0.48) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL4362769 | 0.83 | MAPK10 (0.49) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL3336432 | 0.83 | BRAF (0.48) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL3333630 | 0.82 | PIK3CG (0.54) | SMN1; SMN2BRAFKMT2AKDM4EMEN1 | |
| SCHEMBL3336752 | 0.80 | BRAF (0.46) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL3331750 | 0.80 | TTK (0.48) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 | |
| SCHEMBL3338081 | 0.80 | BRAF (0.46) | SMN1; SMN2L3MBTL1HTTBRAFMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | SMN1; SMN2 3749/4885L3MBTL1 3418/4885HTT 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.